Table of Contents
Managing type 2 diabetes effectively requires staying informed about the latest developments in oral medications. Recent research has significantly expanded our understanding of how these medications work, their safety profiles, and their broader health benefits beyond blood sugar control. This comprehensive guide explores the newest findings on oral diabetes medications, helping patients and healthcare providers make evidence-based treatment decisions.
Understanding Oral Diabetes Medications
Oral diabetes medications represent a cornerstone of type 2 diabetes management, offering convenient alternatives or complements to insulin therapy. These medications work through various mechanisms to help control blood glucose levels, and recent research has revealed benefits that extend far beyond glycemic control. The landscape of diabetes treatment has evolved dramatically, with newer medication classes demonstrating remarkable cardiovascular and renal protective effects that have transformed how clinicians approach diabetes care.
The primary goal of oral diabetes medications is to lower blood glucose levels and reduce hemoglobin A1c (HbA1c), a measure of average blood sugar over the past two to three months. However, modern diabetes management recognizes that optimal treatment must address the multiple complications associated with diabetes, including cardiovascular disease, kidney dysfunction, and metabolic disorders. This holistic approach has led to the development and refinement of medication classes that offer multifaceted benefits.
SGLT2 Inhibitors: Revolutionary Cardiovascular and Renal Protection
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, have transformed the management of type 2 diabetes mellitus (T2DM) by providing glucose-lowering efficacy together with cardiovascular and renal protection. These medications work by blocking glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and subsequent blood sugar reduction.
Mechanism of Action and Glucose Control
The mechanism of action of SGLT2 inhibitors involves inhibiting glucose reabsorption within the proximal renal tubules, resulting in glucosuria, modest weight loss, and blood pressure reduction. This unique approach to glucose management operates independently of insulin, making these medications effective across various stages of diabetes progression.
SGLT2 inhibitors are effective in reducing glucose levels, but the magnitude of reduction varies compared to other classes of antidiabetics. Clinical studies have demonstrated consistent improvements in glycemic control, with patients experiencing meaningful reductions in HbA1c levels when SGLT2 inhibitors are added to their treatment regimen.
Cardiovascular Benefits
One of the most significant discoveries in recent diabetes research involves the cardiovascular benefits of SGLT2 inhibitors. A noticeable reduction in the risk of major cardiovascular events, cardiovascular and all-cause mortality was reported, particularly compared to DPP-4 inhibitors and placebo. These findings have fundamentally changed how physicians prescribe diabetes medications, particularly for patients with existing cardiovascular risk factors.
SGLT2 inhibitors demonstrated the most pronounced and consistent benefits in reducing hospitalisation for heart failure among all other evaluated classes. Initially approved as adjuncts to diet and exercise for glycemic control, these agents now have expanded indications that include reducing hospitalizations for heart failure, preserving renal function, and lowering cardiovascular mortality in patients with or without diabetes.
SGLT2 inhibitors improve HF outcomes in patients with HF, T2DM, CKD, and any combination of these diseases, with a consistent but more modest benefit on CV death. This broad applicability makes SGLT2 inhibitors valuable for diverse patient populations with multiple comorbidities.
Renal Protection and Kidney Disease Management
Renal outcomes consistently favoured SGLT2 inhibitors in reducing the risk of acute kidney injury, slowing chronic kidney disease and lowering the risk of end-stage kidney disease. This renal protective effect represents a major advancement in diabetes care, as kidney disease is one of the most serious complications of diabetes.
Inhibition of glucose reabsorption by SGLT2 in the kidney is a promising strategy for the treatment of diabetic nephropathy. Recent research from 2026 has focused on developing even more selective SGLT2 inhibitors to maximize therapeutic benefits while minimizing side effects. Adverse side effects of SGLT1 inhibition can be reduced by selective inhibition of SGLT2.
An initial, reversible dip in eGFR upon initiation of SGLT2 inhibitor therapy is an expected hemodynamic effect and does not warrant discontinuation. Treatment may be continued even if eGFR falls below the 20 ml/min/1.73 m² initiation threshold until kidney replacement therapy is required. This guidance helps clinicians confidently continue therapy even when kidney function appears to decline initially.
Next-Generation SGLT2 Inhibitors
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have substantially reshaped the management of type 2 diabetes mellitus (T2DM), owing not only to their glucose-lowering properties but also to their consistent cardiovascular and renal protective effects. Beyond their initial metabolic indication, these agents have emerged as disease-modifying therapies across a broad spectrum of cardiometabolic and renal conditions.
This review highlights the evolving pharmacological landscape of SGLT2-based therapies, reflecting a transition from conventional glucose-lowering drugs toward next-generation disease-modifying interventions in cardiovascular and renal medicine. While first-generation SGLT2 inhibitors have firmly established robust benefits in heart failure and chronic kidney disease across diabetic and non-diabetic populations, emerging strategies suggest that newer SGLT2-based approaches may engage additional and qualitatively distinct mechanisms.
Emerging Applications and Future Research
Preliminary evidence hints at neuroprotective effects that may lower stroke risk and cerebral inflammation, especially in DM patients, as well as reducing risk of developing dementia and Alzheimer disease. There is even speculation that SGLT2is could reduce certain cancer risks, such as breast and colon cancer, by lowering hyperglycemia and insulin levels, though this area requires further research.
Preliminary studies suggest that SGLT2is may even have benefits in conditions such as kidney stone prevention, anemia, and possibly in non-cardiometabolic disorders like sepsis and cirrhotic ascites. These potential applications demonstrate the wide-ranging effects of SGLT2 inhibitors beyond traditional diabetes management.
DPP-4 Inhibitors: Safe and Effective Glucose Management
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent another important class of oral diabetes medications that have gained widespread acceptance due to their favorable safety profile and consistent glucose-lowering effects. These medications work by preventing the breakdown of incretin hormones, which naturally stimulate insulin secretion in response to meals.
How DPP-4 Inhibitors Work
These inhibitors prevent the degradation of incretin (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) by dipeptidyl peptidase-4 enzymes and therefore elevate endogenous GLP-1 levels. GLP-1 stimulates insulin secretion from β-cells in a glucose-dependent manner, suppresses glucagon secretion from α-cells, and inhibits hepatic glucose production, eventually contributing to the antihyperglycemic effect.
The DPP-4 inhibitors available demonstrate a high efficacy in inhibiting DPP-4, and under clinical conditions DPP-4 is inhibited by >80–90%. This inhibition consecutively leads to post-prandial GLP-1 plasma concentrations that are elevated 2-3-fold and mediates the glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion.
Glycemic Efficacy
All approved DPP-4 inhibitors appear to have similar glycemic efficacy resulting in moderate (0.5–0.8%) reduction in HbA1c. The DPP-4 inhibitors appear to have similar glycemic efficacy. They result in modest improvement in glycated hemoglobin (HbA1c), with a reduction of ~0.5–1% when used as monotherapy and ~0.6%–1.1% when used in combination with metformin, depending on agent, dose of therapy, and starting HbA1c.
Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA(1c) reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the advantage of no weight gain). In metformin-treated patients, gliptins were associated with similar HbA(1c) reductions compared with a sulphonylurea (SU; with the advantage of no weight gain, considerably fewer hypoglycaemic episodes and no need for titration) and a TZD (with the advantage of no weight gain and better overall tolerability).
Combination Therapy with Insulin
Several clinical trials also showed a consistent reduction in HbA(1c) when DPP-4 inhibitors were added to basal insulin therapy, with no increased risk of hypoglycaemia. This makes DPP-4 inhibitors particularly valuable for patients who require insulin but want to minimize the risk of low blood sugar episodes.
The addition of sitagliptin (100 mg/day) significantly reduced HbA1c by 0.6% compared with placebo (0.0%), with a higher proportion of patients achieving an HbA1c level < 7%. These results demonstrate the additive benefits of combining DPP-4 inhibitors with other diabetes medications.
Safety Profile and Tolerability
DPP-4 inhibitors have shown good safety- and tolerability profiles in the phase III clinical study programs and the most frequent adverse events observed were nasopharyngitis and skin lesions. In most studies, the adverse events did not lead to treatment discontinuation.
The efficacy and safety profile of the DPP-4 inhibitors shows a favorable profile of the DPP-4 inhibitors especially for patients with renal impairment as well as elderly subjects with type-2-diabetes. In clinical use monitored by post-marketing surveillance and in the long-term cardiovascular safety studies, no serious imbalances in safety signals were observed.
They are all apparently well tolerated (side-effect profile resembles placebo) and result in clinically meaningful reductions in blood glucose (fasting and postprandial) and HbA1c levels, with minimal risk of hypoglycemia and without weight gain. This favorable profile makes DPP-4 inhibitors suitable for a wide range of patients, including those at higher risk for hypoglycemia.
Cardiovascular Safety
Both DPP-4 inhibitors and GLP-1 RAs have demonstrated safety in robust cardiovascular outcome trials, while several GLP-1 RAs have been shown to significantly reduce the risk of major adverse cardiovascular events in persons with T2DM with pre-existing cardiovascular disease (CVD). The side effect profile of DPP-4 inhibitors is favorable, there are few treatment-limiting adverse effects and DPP-4 inhibitors have shown cardiovascular safety.
The latest research points that SGLT-2 inhibitors and GLP-1 receptor agonists both reduce cardiovascular events (no study has compared their respective potency in this respect), whereas DPP-4 inhibitors are neutral. While DPP-4 inhibitors don’t actively reduce cardiovascular events like SGLT2 inhibitors, their cardiovascular safety profile makes them appropriate for patients with heart disease.
Use in Special Populations
Another favorable characteristic of the DPP-4 inhibitors is their efficacy and safety profile in patients with impaired renal function. In an analysis of 811 participants in two phase-3 randomized placebo-controlled trials of linagliptin, placebo-adjusted mean HbA1c changes from baseline were − 0.59% (mild renal impairment) and − 0.69% (moderate renal impairment) after 24 weeks and − 0.43% (severe renal impairment) after 12 weeks of therapy.
Metformin: The Cornerstone of Diabetes Treatment
Metformin remains the first-line medication for most patients with type 2 diabetes due to its proven efficacy, safety record, and affordability. This medication has been used for decades and continues to be a fundamental component of diabetes management strategies worldwide.
Why Metformin Remains First-Line
Metformin works primarily by reducing glucose production in the liver and improving insulin sensitivity in muscle tissue. Its long track record of safety and effectiveness, combined with its low cost and minimal risk of hypoglycemia, makes it the preferred initial medication for most patients newly diagnosed with type 2 diabetes.
The medication also offers modest weight loss benefits, which is particularly valuable for overweight or obese patients with type 2 diabetes. Unlike some other diabetes medications that can cause weight gain, metformin’s weight-neutral or weight-reducing effects align well with overall diabetes management goals.
Combination Therapy Approaches
Because of the complex pathophysiology of type 2 diabetes and the complementary actions of glucose-lowering agents, initial combination of a DPP-4 inhibitor with either metformin or a glitazone may be applied in drug-naive patients, resulting in greater efficacy and similar safety compared with either drug as monotherapy.
Metformin serves as an excellent foundation for combination therapy with newer medication classes. When metformin alone doesn’t achieve target blood glucose levels, adding an SGLT2 inhibitor or DPP-4 inhibitor can provide additional glycemic control while leveraging the complementary mechanisms of action.
Gastrointestinal Side Effects and Management
The most common side effects of metformin involve the gastrointestinal system, including nausea, diarrhea, and abdominal discomfort. These effects are typically mild and often resolve with continued use or by taking the medication with food. Extended-release formulations of metformin can help minimize these side effects while maintaining therapeutic effectiveness.
For patients who cannot tolerate metformin due to gastrointestinal side effects, alternative first-line options may include DPP-4 inhibitors or SGLT2 inhibitors, particularly if the patient has cardiovascular or renal disease that would benefit from the protective effects of SGLT2 inhibitors.
Safety Considerations Across Medication Classes
Understanding the safety profiles of different oral diabetes medications helps patients and healthcare providers make informed treatment decisions. Each medication class has specific considerations that should be evaluated based on individual patient characteristics and health status.
SGLT2 Inhibitor Safety Concerns
While SGLT2 inhibitors offer significant benefits, they come with specific safety considerations. The most common side effects include genital yeast infections and urinary tract infections, which occur because increased glucose in the urine creates an environment conducive to fungal and bacterial growth. These infections are generally mild and treatable with standard antimicrobial therapy.
Volume depletion and dehydration represent another concern, particularly in elderly patients or those taking diuretics. Patients should be counseled to maintain adequate hydration and monitor for symptoms of dehydration, especially during hot weather or illness.
Diabetic ketoacidosis, though rare, has been reported with SGLT2 inhibitor use, sometimes occurring even when blood glucose levels are not severely elevated. This atypical presentation, called euglycemic diabetic ketoacidosis, requires awareness among both patients and healthcare providers.
DPP-4 Inhibitor Safety Profile
Each one of the DPP-4 inhibitors is a unique chemical entity and may exhibit a profile of adverse events specific to that chemical entity, which may not be generalizable as a “class effect”. Generally, the DPP-4 inhibitors comprise of a group of chemically diverse compounds, which differ in terms of their potency to inhibit the DPP-4 enzyme, their duration of action and their metabolism and elimination, as well as isolated compound-specific characteristics.
Joint pain has been reported with DPP-4 inhibitors, though this side effect is relatively uncommon. Pancreatitis has also been a concern, though large-scale studies have not definitively established a causal relationship. Healthcare providers should remain vigilant for symptoms of pancreatitis, including severe abdominal pain, and discontinue the medication if pancreatitis is suspected.
Drug Interactions
Because cytochrome P450 isoenzyme CYP3A4/5 metabolizes saxagliptin to its primary metabolite, strong CYP3A4/5 inhibitors, such as diltiazem, ketoconazole, and ritonavir, may increase saxagliptin exposure and thus one should consider dose reduction when co-administering these compounds. P-glycoprotein and CYP3A4 inducers, such as rifampicin, may decrease the efficacy of linagliptin.
DPP-4 inhibitors and other oral hypoglycaemics such as metformin, sulphonylureas or thiazolidinediones have not exhibited any concerted pharmacokinetics. There are no prominent interactions with lipid reducing agents or with hormonal contraception. Anticoagulation potency of warfarin is not affected. Dose adjustment of digoxin is not recommended for administration of DPP-4 inhibitors.
Personalized Medicine and Treatment Selection
Modern diabetes care increasingly emphasizes personalized treatment approaches that consider individual patient characteristics, comorbidities, preferences, and treatment goals. This precision medicine approach helps optimize outcomes while minimizing adverse effects and treatment burden.
Patient-Centered Decision Making
Their broad clinical applicability creates the potential to address individual patient profiles, accounting for factors such as variations in renal function, cardiovascular risk, and metabolic conditions. The success of SGLT2is across a spectrum of conditions underscores their ability to target common pathophysiological mechanisms—such as sodium retention, inflammation, and oxidative stress—that contribute to multiple chronic conditions. By integrating SGLT2 inhibitors into precision medicine frameworks, clinicians can enhance patient care by selecting the appropriate therapy based on an individual’s risk factors, comorbidities, and treatment goals, ultimately improving health outcomes across diverse populations.
When selecting oral diabetes medications, healthcare providers should consider multiple factors including baseline HbA1c levels, presence of cardiovascular or kidney disease, risk of hypoglycemia, weight management goals, cost considerations, and patient preferences regarding route of administration and dosing frequency.
Comorbidity-Driven Treatment Selection
For patients with established cardiovascular disease or heart failure, SGLT2 inhibitors offer clear advantages due to their proven cardiovascular benefits. Similarly, patients with chronic kidney disease benefit from the renal protective effects of SGLT2 inhibitors, making them a preferred choice in this population.
Elderly patients or those at high risk for hypoglycemia may benefit from DPP-4 inhibitors or SGLT2 inhibitors, both of which have minimal hypoglycemia risk when used without insulin or sulfonylureas. The glucose-dependent mechanism of DPP-4 inhibitors makes them particularly safe in this regard.
Cost and Access Considerations
There is no cost-effectiveness advantage for the use of SGLT2is over metformin for first-line therapy in DM. An analysis found an ICER of $478,000 per QALY for the use of SGLT2is over metformin as first-line therapy, noting that SGLT2i costs would need to be reduced by 70% to meet a willingness to pay threshold of $150,000 per QALY.
For use in CKD, SGLT2is have demonstrated themselves to be cost-effective options to the addition to standard of care in the United States. This has been demonstrated in patients with both diabetic CKD ($25,974 per QALY) and in patients with non-diabetic CKD ($60,000 per QALY).
Despite strong clinical evidence, real-world implementation of SGLT2 inhibitors is influenced by cost, reimbursement policies, and healthcare system constraints. Cost-effectiveness analyses generally support their use in heart failure and CKD, particularly in high-risk populations where absolute risk reduction is greatest. However, access disparities persist, especially in low- and middle-income settings, potentially limiting the population-level impact of these therapies.
Combination Therapy Strategies
Most patients with type 2 diabetes eventually require more than one medication to achieve and maintain target blood glucose levels. Understanding how different medication classes work together helps optimize treatment regimens while minimizing side effects and treatment complexity.
Dual Therapy Approaches
When metformin monotherapy proves insufficient, adding a second agent becomes necessary. The choice of second agent should be guided by patient-specific factors including comorbidities, hypoglycemia risk, weight considerations, and cost. SGLT2 inhibitors and DPP-4 inhibitors both represent excellent second-line options with complementary mechanisms of action to metformin.
The combination of metformin with an SGLT2 inhibitor offers the advantage of addressing multiple pathophysiological defects in diabetes while providing cardiovascular and renal protection. This combination is particularly appropriate for patients with or at high risk for cardiovascular or kidney disease.
Metformin combined with a DPP-4 inhibitor provides effective glucose control with minimal hypoglycemia risk and no weight gain. This combination works well for patients who need additional glycemic control but want to avoid the potential side effects associated with other medication classes.
Triple Therapy and Beyond
Apart from the above mentioned indication and placement, DPP-4 inhibitors can also be administered in triple combination treatment with either metformin and SGLT-2 inhibitors or with metformin and insulin. In combination with insulin, some studies have shown a reduction in hypoglycaemic episodes due to a reduction in the insulin dose.
As diabetes progresses, some patients require three or more medications to achieve target glucose levels. Triple therapy typically involves metformin as the foundation, combined with two additional agents from different classes. Common triple therapy regimens include metformin, an SGLT2 inhibitor, and a DPP-4 inhibitor, or metformin, an SGLT2 inhibitor, and insulin.
The key to successful combination therapy lies in selecting medications with complementary mechanisms of action while considering the cumulative side effect profile and treatment burden. Healthcare providers should regularly reassess medication regimens to ensure they remain appropriate as patient circumstances change.
Emerging Research and Future Directions
The field of diabetes pharmacotherapy continues to evolve rapidly, with ongoing research exploring new applications for existing medications and developing novel therapeutic approaches. Understanding these emerging trends helps patients and providers anticipate future treatment options.
Expanding Indications for Existing Medications
Sodium-glucose cotransporter-2 inhibitors are now approved for a variety of clinical indications, including heart failure, chronic kidney disease, and type 2 diabetes mellitus, with increasing interest in management of steatotic diseases of the liver and weight loss. Investigations into SGLT2i and GLP-1 agonists in the treatment of NAFLD are underway as well.
Research continues to uncover new potential applications for diabetes medications beyond their original indications. Studies are investigating whether SGLT2 inhibitors might benefit patients with conditions ranging from polycystic kidney disease to certain types of heart failure, even in the absence of diabetes.
Novel Drug Formulations and Delivery Systems
Pharmaceutical companies are developing new formulations of existing medications to improve convenience, adherence, and efficacy. Fixed-dose combinations that include multiple medications in a single pill can simplify treatment regimens and improve adherence, particularly for patients taking multiple medications.
Extended-release formulations and once-weekly dosing options are being explored for various medication classes. These innovations aim to reduce pill burden and improve patient satisfaction with treatment, potentially leading to better long-term outcomes.
Precision Medicine Approaches
Key limitations of the current evidence base include reliance on emerging or indirect mechanistic data, heterogeneity in study populations and clinical endpoints, and the relative scarcity of large, outcome-driven trials for newer SGLT2-based therapies. Future research should prioritize mechanism-driven clinical trials, precision-oriented patient stratification, and head-to-head comparisons.
Researchers are working to identify biomarkers and genetic factors that predict which patients will respond best to specific medications. This precision medicine approach could eventually allow healthcare providers to select the most effective medication for each individual patient based on their unique biological characteristics, rather than relying solely on trial-and-error approaches.
Addressing Implementation Barriers
Real-world surveys and qualitative work in the United States, Canada, and Australia/New Zealand consistently identify clinical inertia, high out-of-pocket costs, prior-authorization requirements, formulary restrictions, and the perception of SGLT2 inhibitors as “diabetes-only” medications as key barriers to uptake in heart failure.
Despite this, the adoption of the drug class into clinical practice remains suboptimal, hindered by cost and clinician familiarity. Addressing these barriers through education, policy changes, and improved access will be essential to ensuring that patients benefit from the latest advances in diabetes pharmacotherapy.
Practical Considerations for Patients
Successfully managing diabetes with oral medications requires more than just taking pills. Patients need to understand their medications, monitor for side effects, and work collaboratively with their healthcare team to optimize treatment outcomes.
Medication Adherence
Taking medications as prescribed is crucial for achieving target blood glucose levels and preventing complications. Patients should establish routines that help them remember to take their medications consistently, such as taking them at the same time each day or using pill organizers and reminder apps.
Understanding why each medication is prescribed and how it works can improve motivation to adhere to treatment. Patients should feel comfortable asking their healthcare providers questions about their medications and expressing concerns about side effects or cost.
Monitoring and Follow-Up
Regular monitoring of blood glucose levels and HbA1c helps assess whether medications are working effectively. Patients should attend scheduled follow-up appointments and report any concerning symptoms or side effects to their healthcare providers promptly.
Self-monitoring of blood glucose provides valuable information about how medications, diet, exercise, and other factors affect blood sugar levels. This data helps healthcare providers make informed decisions about medication adjustments and treatment optimization.
Lifestyle Modifications
Oral diabetes medications work best when combined with healthy lifestyle habits. A balanced diet, regular physical activity, adequate sleep, and stress management all contribute to better blood glucose control and overall health. Medications should be viewed as one component of a comprehensive diabetes management plan, not a replacement for healthy lifestyle choices.
Weight management is particularly important for patients with type 2 diabetes, as excess weight contributes to insulin resistance. Some diabetes medications can support weight loss efforts, while others may cause weight gain. Discussing weight goals with healthcare providers can help guide medication selection.
Key Takeaways for Patients and Providers
The landscape of oral diabetes medications has evolved dramatically in recent years, offering patients and healthcare providers more options than ever before for managing type 2 diabetes effectively. SGLT2 inhibitors have emerged as transformative medications that provide not only glucose control but also significant cardiovascular and renal protection, making them particularly valuable for patients with or at risk for these complications.
DPP-4 inhibitors offer safe and effective glucose lowering with minimal side effects and hypoglycemia risk, making them appropriate for a wide range of patients, including the elderly and those with kidney disease. Metformin remains the cornerstone of diabetes treatment due to its proven efficacy, safety, and affordability, serving as an excellent foundation for combination therapy when needed.
Personalized treatment approaches that consider individual patient characteristics, comorbidities, preferences, and goals represent the future of diabetes care. By selecting medications based on each patient’s unique circumstances rather than following a one-size-fits-all approach, healthcare providers can optimize outcomes while minimizing side effects and treatment burden.
Ongoing research continues to expand our understanding of how these medications work and identify new applications beyond glucose control. Staying informed about the latest evidence helps patients and providers make the best possible treatment decisions and take advantage of new therapeutic options as they become available.
For more information about diabetes management and treatment options, visit the American Diabetes Association or consult with your healthcare provider. The National Institute of Diabetes and Digestive and Kidney Diseases also provides comprehensive resources for patients and families affected by diabetes.
Understanding your medications, maintaining open communication with your healthcare team, adhering to prescribed treatments, and embracing healthy lifestyle habits all contribute to successful diabetes management. With the right combination of medications and self-care strategies, most people with type 2 diabetes can achieve target blood glucose levels and reduce their risk of complications, leading to longer, healthier lives.